- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02969720
Therapeutic Efficacy of Phytosterols on Metabolic Syndrome (FESIME)
March 14, 2020 updated by: Yasna Palmeiro-Silva, Universidad de los Andes, Chile
Double Blind, Randomized, Phase III, Parallel, Placebo-controled Study to Evaluate Therapeutic Efficacy of 2 Grams Phytosterols Daily Supplemention on Patients With Metabolic Syndrome
The objective is to evaluate therapeutic efficacy of 2 grams nano-phytosterols daily supplemention on diagnosis criteria of metabolic syndrome.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
220
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Santiago, Chile
- Universidad de Los Andes
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed consent written
- Available subjects to follow-up visits
- Subjects with diagnoses of metabolic syndrome 5 years ago or with current diagnoses criteria
- Subjects with health visits ongoing
- Subjects with arterial hypertension under control.
- Subjects with mellitus diabetes under control.
Exclusion Criteria:
- Subjects with alcoholism history.
- Subjects with history of sitosterolemia.
- Subjects with familiar hypercholesterolemia
- Subjects who are consuming phytosterols
- Pregnancy women
- Breastfeeding period women
- Subjects with personal history of: acute miocardical infarction, stroke, hypertensive emergency, acute or chronic diabetes descompensation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phytosterol
Daily consumption of 2 grams (8 ml) nano-phytosterols per 180 days.
|
Oral daily consumption of 2 grams of phytosterols (8 ml) per 180 days.
Other Names:
|
Placebo Comparator: Placebo
Daily consumption of 8 ml of a solution with Titanium Dioxide per 180 days.
|
Oral daily consumption of Titanium Dioxide (8 ml) per 180 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference of proportion between study groups in the proportion of metabolic syndrome from baseline and the last visit (180 days).
Time Frame: 180 days
|
180 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2018
Primary Completion (Actual)
November 27, 2018
Study Completion (Actual)
November 27, 2018
Study Registration Dates
First Submitted
November 17, 2016
First Submitted That Met QC Criteria
November 17, 2016
First Posted (Estimate)
November 21, 2016
Study Record Updates
Last Update Posted (Actual)
March 17, 2020
Last Update Submitted That Met QC Criteria
March 14, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FESIME-016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
PI will share IPD after doing all possible publications.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome x
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Federal University of São PauloCompletedPhysical Activity | Endothelial Dysfunction | Metabolic Syndrome xBrazil
-
Midwest Biomedical Research FoundationSuspended
-
Instituto de Seguridad y Servicios Sociales de...Enrolling by invitationCardiovascular Diseases | Mediterranean Diet | Metabolic Syndrome xMexico
-
Wake Forest University Health SciencesBrigham and Women's HospitalCompletedDiabetes | Metabolic Syndrome xUnited States
-
University of PennsylvaniaAbbottCompletedMetabolic Syndrome xUnited States
-
Queen Margaret UniversityUnknownCardiovascular Diseases | Metabolic Syndrome XUnited Kingdom
-
Arne AstrupUniversity of Aarhus; University Hospital, Gentofte, Copenhagen; Technical University...CompletedMetabolic Syndrome XDenmark
-
Arne AstrupUniversity of Aarhus; University Hospital, Gentofte, Copenhagen; Technical University...Completed
Clinical Trials on Phytosterols
-
Danone JapanCompleted
-
Danone JapanCompletedSubjects With High LDL-CholesterolJapan
-
China Medical University HospitalCompleted
-
Puerta de Hierro University HospitalCompletedHypercholesterolemia | OsteoporosisSpain
-
University of ManitobaCompleted
-
Washington University School of MedicinePennington Biomedical Research CenterCompletedHypercholesterolemia | Coronary Heart DiseaseUnited States
-
Hoffmann-La RocheTerminatedCardiovascular DiseasePoland, United States, Switzerland, Canada, Germany
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI); Utah State UniversityCompletedHypercholesterolemia | Coronary Heart DiseaseUnited States
-
Puerta de Hierro University HospitalCompletedPostmenopausal DisorderSpain
-
University of PaviaFoundation IRCCS San Matteo HospitalRecruiting